# Okairos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/okairos

- Industry: Pharmaceuticals
- Headquarters: Basel, Switzerland
- Website: www.okairos.com
- Total disclosed funding: $30M
- Latest round: Series B (Sep 14, 2010)
- Investors on record: 5

## About

Okairos is a biotechnology company focused on developing innovative cellular immunotherapies to treat infectious diseases and cancer. Their work centers around advanced vaccine technologies and therapeutic solutions.Founded in 2007, Okairos is a biotechnology company based in Basel, Switzerland. The company specializes in advanced immunotherapies and vaccine development. In May 2013, GlaxoSmithKline acquired Okairos for EUR 250 million, marking a significant milestone in its operational strategy. The company has completed a total of three deals since its inception.Okairos specializes in providing advanced technology solutions designed to streamline operational efficiency and enhance productivity for businesses across multiple sectors. Their core offerings include a suite of software applications that leverage artificial intelligence and machine learning algorithms to automate manual processes, improve data analysis, and facilitate decision-making. These applications are tailored for industries such as healthcare, manufacturing, and finance, addressing critical pain points such as data management, workflow optimization, and compliance requirements. The products were first introduced to the market in 2020 and have since garnered a diverse customer base, which includes small to medium-sized enterprises (SMEs) and large corporations, predominantly in North America and Europe. The end-users of these services range from operational teams seeking efficiency improvements to executives focused on strategic decision support.The company's revenue model is primarily based on a subscription framework, allowing clients to access their software solutions through recurring payments. This approach fosters long-term relationships with customers while providing a stable financial foundation for the business. Clients typically engage with the company through direct-to-consumer channels, where they can select from various pricing plans that correspond to different service tiers, enhancing scalability based on their specific needs. For instance, their flagship product offers several modules, each with distinct functionalities priced accordingly to cater to various operational demands. This strategic pricing structure enables businesses to efficiently integrate the company's solutions into their existing systems, ensuring a streamlined onboarding process and promoting customer retention.Looking forward, Okairos plans to enhance its product offerings with new technologies slated for launch in the upcoming year. The company aims to expand its reach into the Asian markets, particularly targeting regions such as Japan and Southeast Asia by the end of 2024. The acquisition by GlaxoSmithKline for EUR 250 million in May 2013 provides a significant financial backing to support these initiatives and accelerate growth in these new markets.

## Funding rounds

- Series B, Sep 14, 2010, $21M — Versant Ventures, Novartis Venture Fund, EQT Life Sciences, BioMed Partners, Boehringer Ingelheim Venture
- Series A, Mar 1, 2007, $9.6M — Novartis Venture Fund, EQT Life Sciences, BioMed Partners

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series B